A favorable safety profile with minimal or minor adverse events has been documented in almost all classes of biological drugs; opportunistic infections are associated with anti-CD-20 inhibitors and TNF-α inhibitors, and there has been a transitory increase in HIV viral load with some biological agents like TNF-alpha inhibitors. The gene discussed is TNF; the disease is Opportunistic infection.